[The return of the hepatitis delta virus]

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis delta virus (HDV) infects individuals already carrying the hepatitis B virus (HBV).
• HDV infection is increasingly prevalent globally due to immigration, posing a significant public health challenge.
• HDV is transmitted via the same routes as HBV, through co-infection or superinfection.

Purpose of the Study:

• To review the epidemiology, clinical significance, and therapeutic landscape of chronic HDV infection.
• To highlight the severity of delta hepatitis and its association with cirrhosis and hepatocellular carcinoma.
• To discuss current treatment limitations and emerging therapeutic strategies.

Main Methods:

• Review of existing literature on HDV epidemiology and clinical presentation.
• Analysis of transmission routes and risk factors for chronic HDV infection.
• Evaluation of current therapeutic options and ongoing clinical trials for novel antivirals.

Main Results:

• Delta hepatitis represents the most severe form of viral hepatitis, with high progression rates to advanced liver disease.
• Pegylated interferon, the sole approved therapy, offers limited efficacy, with few patients achieving a sustained virological response or cure.
• Emerging therapies, including viral entry inhibitors and prenylation inhibitors, are under investigation.

Conclusions:

• Chronic HDV infection in HBV carriers is a serious condition requiring effective treatment strategies.
• Current therapies are insufficient, necessitating the development of new interventions.
• Promising novel antiviral agents are in development and clinical trials, offering hope for improved patient outcomes.